• LAST PRICE
    2.6550
  • TODAY'S CHANGE (%)
    Trending Up0.0450 (1.7241%)
  • Bid / Lots
    2.5700/ 2
  • Ask / Lots
    2.7100/ 2
  • Open / Previous Close
    2.6700 / 2.6100
  • Day Range
    Low 2.4600
    High 2.7019
  • 52 Week Range
    Low 1.8350
    High 71.8500
  • Volume
    88,714
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 2.61
TimeVolumeTHAR
09:32 ET46912.62
09:33 ET3002.57
09:39 ET1002.57
09:46 ET5002.57
09:50 ET26002.46
10:04 ET1212.5331
10:18 ET1952.5541
10:26 ET1352.5003
10:31 ET17632.51
10:33 ET4002.51
10:40 ET1402.52
10:47 ET11002.59
10:49 ET2002.59
10:58 ET49192.585
11:00 ET66922.6291
11:02 ET12002.63
11:03 ET47092.66
11:05 ET21002.65
11:12 ET21002.64
11:20 ET12002.65
11:21 ET31702.67
11:23 ET41182.63
11:25 ET9002.62
11:32 ET2002.6
11:34 ET4942.6
11:38 ET10002.5988
12:26 ET2002.62
12:37 ET24882.62
12:39 ET2002.62
12:42 ET79312.6392
12:44 ET21002.66
12:46 ET39992.69
12:53 ET116102.68
12:55 ET55582.65
12:57 ET10632.655
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTHAR
Tharimmune Inc
3.9M
-0.1x
---
United StatesPLRZ
Polyrizon Ltd
3.9M
-3.9x
---
United StatesATXI
Avenue Therapeutics Inc
3.8M
-0.2x
---
United StatesCYCN
Cyclerion Therapeutics Inc
3.8M
-0.7x
---
United StatesTNFA
TNF Pharmaceuticals Inc
3.7M
-0.2x
---
United StatesKTTA
Pasithea Therapeutics Corp
4.0M
-0.2x
---
As of 2024-11-22

Company Information

Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.

Contact Information

Headquarters
1200 Route 22 EastBRIDGEWATER, NJ, United States 08807
Phone
302-743-2995
Fax
302-645-1280

Executives

Chairman of the Board, President, Chief Executive Officer
Randy Milby
Chief Financial Officer
Thomas Hess
Chief Operating Officer, Director
Sireesh Appajosyula
Independent Director
Kelly Anderson
Independent Director
Lynne Bui

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.9M
Revenue (TTM)
$0.00
Shares Outstanding
1.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-18.44
Book Value
$11.67
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.